Every 10-Q that Bausch + Lomb Corporation (BLCO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BLCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLCO filings page.
Bausch + Lomb, a global eye health company, reported Q2 2026 revenue of $1,394 million, up from $1,278 million a year earlier, largely from product sales of $1,389 million. Operating results improved to income of $83 million versus a loss of $11 million, and net loss attributable to the company narrowed to $14 million (loss per share $0.04) from $62 million (loss per share $0.18).
For the first half of 2026, revenue increased to $2,638 million from $2,415 million, while operating income was $116 million compared with a loss of $94 million. Net loss attributable to Bausch + Lomb was $85 million, improved from $274 million. Operating cash flow rose to $185 million from $10 million, after $171 million of capital expenditures and $53 million of acquisitions and other investments.
As of June 30, 2026, the company held $367 million of cash and cash equivalents and total assets of $13,859 million. Principal long-term debt was $5,128 million, including a $2,795 million term loan due 2031 and $1,400 million notes due 2028, with a weighted average stated interest rate of 7.43%. Bausch Health Companies Inc. owned approximately 87% of Bausch + Lomb’s common shares and continues to evaluate a potential separation and related transactions.
Bausch + Lomb Corporation reported first-quarter 2026 results showing higher sales but a continued net loss. Revenues reached $1,244 million, up from $1,137 million a year earlier, driven by product sales across its Vision Care, Pharmaceuticals and Surgical eye-health segments.
Operating income improved to $33 million from an operating loss of $83 million, and the net loss attributable to the company narrowed to $71 million from $212 million, or $0.20 per share versus $0.60. Cash from operating activities was $32 million compared with a $25 million use of cash in the prior-year quarter. As of March 31, 2026, total assets were $13,780 million, long-term debt and other financial liabilities (net of issuance costs) were about $5,039 million, and cash and cash equivalents were $268 million. Bausch Health Companies Inc. continued to own roughly 87% of Bausch + Lomb’s common shares, with 356,536,358 common shares outstanding as of April 22, 2026.
Bausch + Lomb reported Q3 2025 results with revenue of $1,281 million, up from $1,196 million a year ago, and operating income of $95 million versus $43 million. The quarter showed a net loss attributable to the company of $28 million (–$0.08 per share) compared to net income of $4 million ($0.01) last year, reflecting higher interest expense and other below‑the‑line items despite stronger operations.
For the first nine months, revenue reached $3,696 million (from $3,511 million) and the company recorded a net loss of $302 million (from $314 million). Cash from operations was $147 million, while investing cash outflows of $267 million included higher capex. Long‑term debt stood at $4,922 million and cash and equivalents at $310 million as of September 30, 2025. Bausch Health owned about 88% of BLCO as of October 22, 2025, and the planned separation remains subject to conditions. Shares outstanding were 354,189,784 as of October 22, 2025.